Kyowa Kirin Co., Ltd. (TYO:4151)
2,309.50
+27.00 (1.18%)
Oct 22, 2025, 3:30 PM JST
Kyowa Kirin Revenue
Kyowa Kirin had revenue of 125.93B JPY in the quarter ending June 30, 2025, a decrease of -1.16%. This brings the company's revenue in the last twelve months to 493.24B, up 3.62% year-over-year. In the year 2024, Kyowa Kirin had annual revenue of 495.56B with 12.06% growth.
Revenue (ttm)
493.24B
Revenue Growth
+3.62%
P/S Ratio
2.42
Revenue / Employee
87.01M
Employees
5,669
Market Cap
1.19T
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 495.56B | 53.33B | 12.06% |
Dec 31, 2023 | 442.23B | 43.86B | 11.01% |
Dec 31, 2022 | 398.37B | 46.13B | 13.09% |
Dec 31, 2021 | 352.25B | 33.89B | 10.65% |
Dec 31, 2020 | 318.35B | 12.53B | 4.10% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Takeda Pharmaceutical Company | 4.48T |
Otsuka Holdings | 2.40T |
Astellas Pharma | 1.94T |
Daiichi Sankyo Company | 1.92T |
Chugai Pharmaceutical | 1.20T |
Terumo | 1.04T |
Olympus | 969.02B |
HOYA Corporation | 876.09B |
Kyowa Kirin News
- 4 weeks ago - Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy - Seeking Alpha
- 6 weeks ago - Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis - Benzinga
- 6 weeks ago - Amgen (AMGN) and Kyowa Kirin Report Positive Long-term Results for Rocatinlimab - GuruFocus
- 6 weeks ago - Amgen, Kyowa Kirin announce long-term Phase 3 data for eczema drug - Seeking Alpha
- 6 weeks ago - Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from ASCEND Study on Rocatinlimab ... - GuruFocus
- 6 weeks ago - Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from Rocatinlimab Phase 3 ASCEND ... - GuruFocus
- 2 months ago - Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers - GlobeNewsWire
- 2 months ago - Kyowa Kirin Co., Ltd. (KYKOF) Q2 2025 Earnings Call Transcript - Seeking Alpha